Heating up its precision ablation business – Updated 18 October
Yesterday, Clinical Laserthermia (CLS) announced both an exclusive distribution deal and a co-development agreement with MRI Interventions. According to the press release, MRI Interventions will be given the rights to distribute and sell CLS’s portfolio of products in the US and Canada. The companies will also partner up to develop a next-generation navigation and laser ablation platform for spine and neurosurgery, set for launch in 2020.
Enhancing its product offering – Updated 29 August
Clinical Laserthermia Systems (CLS) reported an operating loss of SEK 15.4m in Q2 this year, in line with expectations, compared to a loss of SEK 5.3m in Q2 2017. The increased loss was largely explained by no recognition of Horizon2020 grants this quarter. Instead, CLS will receive SEK 4m in Q4, upon submitting the final project report in November. Operationally, the company has finalised its three EU studies within the communicated time plan. In addition, two new interesting commercial collaborations with Exact Imaging and Image Guided Therapy have recently been announced.
Turning up the heat inside – Updated 9 July
CLS offers advanced products and technology for differentiated thermal cancer treatment. With its method, imILT, the target tumour is heated up through lasers, which destroys it while releasing antigens that activate the immune system to attack any metastatic tumours. Its second method, Focal Laser Ablation (FLA) destroys the tumour through higher heat, but does not provide an immunotherapeutic effect. The global oncology market is posting strong structural underlying growth with immunotherapy as a key driver. CLS estimates that the immunotherapy market will grow at a 2016-21 CAGR of 14%, reaching USD 119bn in 2021.
Marketing material commissioned by Clinical Laserthermia Systems
The information provided within this website is intended for background information only. The views and other information provided herein are the current views of Nordea Markets as of the date of publication and are subject to change without notice. The information provided within this website is not an exhaustive description of the described product or the risks related to it, and it should not be relied on as such, nor is it a substitute for the judgement of the recipient.
The information provided within this website is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information provided within this website has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision. It is important to note that past performance is not indicative of future results.
Nordea Markets is not and does not purport to be an adviser as to legal, taxation, accounting or regulatory matters in any jurisdiction.
The information provided within this website may not be reproduced, distributed or published for any purpose without the prior written consent from Nordea Markets.